Annotation Detail

Information
Associated Genes
BCR
Associated Variants
BCR MUTATION
BCR MUTATION
Associated Disease
Myeloid Leukemia, Chronic
Source Database
DisGeNET
Description
The dynamics of BCR-ABL1 clearance observed in our study suggest that the use of standard or high-dose imatinib or a second-generation tyrosine kinase inhibitor such as nilotinib or dasatinib elicits similar responses when administered as front-line therapy for patients with chronic myeloid leukemia in chronic phase.
Pubmed
25216683
Section of the abstract supporting the evidence
ALL_TEXT_3/3
Number of the section of the abstract supporting the evidence
3
Number of the sentence supporting the evidence
9
Original source reporting the Gene Disease association
BeFree,CTD_human,GAD,LHGDN,ORPHANET
DisGENET score for the Gene Disease association
0.395567170261351
Drugs